Universal Influenza Vaccines 2022

5-7 September 2022, The Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Provisional Conference Programme | Tuesday 6th September 2022

SESSION 5:
IMMUNITY – I

Moderator: Ted M. Ross
(University of Georgia, Athens, Georgia, USA)

‘The art of measuring influenza-specific immunity’
Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘Human T cell immunology of influenza’
Teresa Lambe
(University of Oxford, Oxford, UK)

‘Novel immune correlates of protection against influenza infection’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

‘Immune response profile induced by live M2SR (M2-deficient single replication) influenza vaccine and protection against human challenge with a substantially drifted H3N2 strain’
Joseph Eiden1, Bram Volckaert2, Oleg Rudenko2, Ruth Ellis3, Roger Aitchison4, Renee Herber1, Lawrence Moulton5, Dan Hoft6, David Marshall1 and Pamuk Bilsel1
(1 FluGen, Inc., Madison, Wisconsin, USA; 2 SGS Life Sciences, Antwerp, Belgium; 3 Biologics Consulting, Alexandria, Virginia, USA; 4 North Rim Consulting, Denver, Colorado, USA; 5 Johns Hopkins University, Baltimore, Maryland, USA; 6 Saint Louis University, St. Louis, Missouri, USA)

Coffee Break & Posters

SESSION 6:
IMMUNITY

Moderator: Rob-Lambkin Williams
(Virology Consult, London, UK)

‘Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 protects ferrets and mice against influenza virus challenge’
Teresa Lambe1, M. McMahon2, G. Asthagiri Arunkumar2,3, W.C. Liu2,4, D. Stadlbauer2,5, A. Ioannou2, R.A. Albrecht2,4, V. Pavot1, M. Aramouni1, S.C. Gilbert1 and F. Krammer2
(1 The Jenner Institute, University of Oxford, Oxford, United Kingdom; 2 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 3 Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4 Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 5 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria)

‘Using pseudotypes for immunogenicity testing of universal influenza vaccines’
Nigel J. Temperton
(Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK)

‘Repeat vaccination reduces antibody affinity maturation irrespective of influenza vaccine platform in humans’
Surender Khurana1, Megan Hahn1, Elizabeth M. Coyle1, Lisa R. King1, Tsai-Lien Lin2, John Treanor3, Andrea Sant3 and Hana Golding1
(1 Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 2 Division of Biostatistics, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 3 University of Rochester Medical Center, Rochester, New York, USA)

‘The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice’
Li Song1,2,3,4, Dan Xiong1,2,3,4, Xilong Kang1,2,3,4, Yang Jiao1,2,3,4, Xiaohui Zhou1,2,3,4,5, Kaiyue Wu1,2,3,4, Yi Zhou1,2,3,4, Xinan Jiao1,2,3,4*, and Zhiming Pan1,2,3,4*
(1 Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu, China; 2 Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu, China; 3 Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, Jiangsu, China; 4 Joint International Research Laboratory of Agriculture and Agri-product Safety of the Ministry of Education, Yangzhou University, Yangzhou, Jiangsu, China; ePathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, Connecticut, USA)

Lunch Break & Posters

SESSION 7:
VACCINES – I

Moderator: Yuri Vasiliev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

‘Evaluation of exploratory cellular and humoral responses to FLU-v, a universal influenza peptide vaccine tested in a clinical phase IIb trial’
F. Oftung1, L.M. Næss1, D. B.-Bratlie1, I. Laake1, E. James2, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health, (NIPH) Norway; 2 PepTcell Ltd (trading as SEEK), London, UK)

‘Next Generation H2 COBRA Hemagglutinin Vaccines Elicit Broadly Protective Antibodies Against H2Nx Influenza Viruses’
Z. Beau Reneer1, Parker J. Jamieson and Ted M. Ross1,2
(1 Center for Vaccines and Immunology, 2 Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA)

‘Intranasal immunization with Nanovax-rH5 vaccine (NanovaxrH5-NE01) induced Non-HAI antibodies that protected ferrets against a lethal heterologous clade of pandemic H5 flu challenge’
Ali Fattom
(Bluewillow Biologics. Ann Arbor, Michigan, USA)

‘Development of a broadly-protective M2e-based universal live attenuated influenza vaccine’
Irina Isakova-Sivak, Daria Mezhenskaya, Tatiana Kotomina, Victoria Matyushenko, Anastasia Evsina, Polina Prokopenko and Larisa Rudenko
(Institute of Experimental Medicine, St. Petersburg, Russia)

Tea Break & Posters

SESSION 8:
MODELS

Moderator: Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘The pig influenza challenge model’
Elma Tchilian
(The Pirbright Institute, Pirbright, Surrey, UK)

‘The intratracheal ferret challenge model to demonstrate effectiveness of Live attenuated, adjuvanted whole inactivated and split virus vaccines in preventing severe pneumonia induced by avian influenza’
Jørgen de Jonge1,Harry van Dijken1, Sanne Spijkers1, Justin Mouthaan1, Femke de Heij1, Rineke de Jong2, Paul Roholl3, Irina Isakova-Sivak4, Paulo Lee Ho5, Nicolas Colin6, Karen Smith-Korsholm7 and Larisa Rudenko4
(1 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands; 2 Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands; 3 Microscope Consultancy, Weesp, The Netherlands; 4 Institute of Experimental Medicine, St. Petersburg, Russia: 5 Butantan, Sao Paulo, Brazil; 6 University of Lausanne (UNIL), Lausanne, France; 7 Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark)

‘In vitro assay and animal models for evaluation of Safety and Efficacy of next generation influenza vaccines and therapeutic antibodies’
Juanjie Tang, Laura Klenow, Hana Golding and Surender Khurana
(Division of Viral products, Center for Biologics Evaluation and Research, FDA, Silver Spring Maryland, USA)

 

UIV 2022 Delegates

Login details will be supplied after you have registered for the event.


UIV 2022 Sponsors

  • VisMederi
  • Vaxart
  • APACI
  • ISIRV
  • The Native Antigen Company
  • DNAvaccine.com
  • Sanofi Pasteur
  • BiondVax
  • NanoFCM
  • Izon Science
  • FluConsult

UIV 2022 Mailing List

Name
E-mail Address
What is 3+2-1?